A common characteristic of the above studies was the fact that the reduction in cardiovascular mortality and HF hospitalization was observed early in the treatment period, with SGLT2 inhibitors suggesting their potential beneficial cardiovascular effects in patients without DM [126]. Here, SLC5A2 is linked to diabetes mellitus.